NRC 8-K: Financials & Officer Changes Reported Feb 8, 2024

TL;DR

**NRC just dropped an 8-K on financials and officer changes, keep an eye on leadership and performance.**

AI Summary

National Research Corporation filed an 8-K on February 13, 2024, reporting on events that occurred on February 8, 2024. The filing covers 'Results of Operations and Financial Condition' and 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.' This matters to investors because it signals potential changes in the company's financial performance and leadership, which could impact future stock valuation and strategic direction.

Why It Matters

This filing indicates that National Research Corporation is disclosing important updates regarding its financial health and executive team, which are critical factors for investors assessing the company's stability and growth prospects.

Risk Assessment

Risk Level: medium — The filing mentions 'Results of Operations and Financial Condition' and 'Departure of Directors or Certain Officers,' which could indicate either positive or negative developments, creating uncertainty.

Analyst Insight

A smart investor would closely monitor subsequent filings or press releases from National Research Corporation for detailed information on the 'Results of Operations and Financial Condition' and the specifics of any 'Departure of Directors or Certain Officers' to understand the full impact of these reported events.

Key Players & Entities

• National Research Corporation (company) — the registrant filing the 8-K
• February 8, 2024 (date) — the date of the earliest event reported in the 8-K
• February 13, 2024 (date) — the filing date of the 8-K
• 001-35929 (other) — Commission File Number for National Research Corporation
• NRC (company) — trading symbol for National Research Corporation

FAQ

Filing Documents

• nrc20240209c_8k.htm (8-K) — 32KB
• ex_624952.htm (EX-99.1) — 158KB
• nrc.jpg (GRAPHIC) — 6KB
• 0001437749-24-003940.txt ( ) — 340KB
• nrc-20240208.xsd (EX-101.SCH) — 3KB
• nrc-20240208_def.xml (EX-101.DEF) — 11KB
• nrc-20240208_lab.xml (EX-101.LAB) — 15KB
• nrc-20240208_pre.xml (EX-101.PRE) — 11KB
• nrc20240209c_8k_htm.xml (XML) — 3KB

02

Item 2.02 Results of Operations and Financial Condition. On February 13, 2024, National Research Corporation, a Delaware corporation (the "Company"), issued a press release announcing its financial and operating results for the fourth quarter and year ended December 31, 2023. A copy of the press release is furnished as Exhibit 99.1 to this report and is incorporated by reference herein. On February 14, 2024, the Company will hold a conference call and online Web simulcast in connection with the Company's announcement of its earnings for the fourth quarter and year ended December 31, 2023. An archive of such conference call and simulcast and the related question and answer session will be available online at https://events.q4inc.com/attendee/823574505.

02

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February 8, 2024, Kevin R. Karas, Senior Vice President, Chief Financial Officer, Treasurer and Secretary of the Company notified the Company of his decision to retire effective March 31, 2024. In connection with his retirement, Mr. Karas entered into a Retirement Transition Agreement which provides that he will receive one year of base salary continuation payments from April 1, 2024 through March 31, 2025. The Company and its Board of Directors extend their gratitude to Mr. Karas for his over 13 years of service. Also, on February 8, 2024, the Company's Board of Directors approved the promotion of Linda Stacy, Vice President of Finance, to the position of Principal Accounting Officer, effective on March 31, 2024. The following is biographical information for Ms. Stacy: Linda Stacy , 53, joined the Company as Accounting Controller in 2006 and was promoted to Vice President of Finance in 2008. From 1999 to 2006, Ms. Stacy served in various roles at MDS Pharma Services, a drug discovery and development company. Ms. Stacy started her career as a Certified Public Accountant at BKD CPAs & Advisors.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. EXHIBIT NUMBER EXHIBIT DESCRIPTION 99.1 National Research Corporation press release announcing its financial and operating results for the fourth quarter and year ended December 31, 2023. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). The information contained in Items 2.02 and 9.01 of this report and the exhibits hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. The information in Items 2.02, 5.02, and 9.01 of this report and the exhibits hereto may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act and such statements are subject to the safe harbor created by those sections and the Private Securities Litigation Reform Act of 1995, as amended. Such statements are made based on the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties. Actual results or events may differ from those anticipated by forward-looking statements. Please refer to the paragraph at the end of the attached press release and various disclosures by the Company in its press releases, stockholder reports, and filings with the Securities and Exchange Commission for information concerning risks, uncertainties, and other factors that may affect future results. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NATIONAL RESEARCH CORPORATION (Registrant) Date: February 13, 2024 By: /s/ Kevin R. Karas Kevin R. Karas Senior

View Full Filing

View this 8-K filing on SEC EDGAR